A single arm, multicenter, phase II trial of oxaliplatin plus capecitabine in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC)

被引：0
|
作者：
Tianshu, L. [1 ]
Yu, Y. [1 ]
Sun, Y. [2 ]
Min, Y. [3 ]
Cao, H. [4 ]
Yingbin, L. [5 ]
Wang, Y. [1 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Dept Gen Surg, Coll Med, Shanghai, Peoples R China
[4] Shanghai Renji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
229P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
    Yoshiaki Nakamura
    Takeharu Yamanaka
    Keisho Chin
    Haruhiko Cho
    Hitoshi Katai
    Masanori Terashima
    Kazunari Misawa
    Motohiro Hirao
    Kazuhiro Yoshida
    Eiji Oki
    Mitsuru Sasako
    Yasunori Emi
    Hideaki Bando
    Yoshiyuki Kawashima
    Tetsu Fukunaga
    Masahiro Gotoh
    Takako Ishibashi
    Kohei Shitara
    Annals of Surgical Oncology, 2019, 26 : 465 - 472
  • [32] Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Chin, Keisho
    Cho, Haruhiko
    Katai, Hitoshi
    Terashima, Masanori
    Misawa, Kazunari
    Hirao, Motohiro
    Yoshida, Kazuhiro
    Oki, Eiji
    Sasako, Mitsuru
    Emi, Yasunori
    Bando, Hideaki
    Kawashima, Yoshiyuki
    Fukunaga, Tetsu
    Gotoh, Masahiro
    Ishibashi, Takako
    Shitara, Kohei
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 465 - 472
  • [33] Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma:: a prospective multicentre phase II trial
    Nehls, O.
    Oettle, H.
    Hartmann, J. T.
    Hofheinz, R-D
    Hass, H. G.
    Horger, M. S.
    Koppenhoefer, U.
    Hochhaus, A.
    Stieler, J.
    Trojan, J.
    Gregor, M.
    Klump, B.
    BRITISH JOURNAL OF CANCER, 2008, 98 (02) : 309 - 315
  • [34] Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial
    Monti, Manlio
    Morgagni, Paolo
    Nanni, Oriana
    Framarini, Massimo
    Saragoni, Luca
    Marrelli, Daniele
    Roviello, Franco
    Petrioli, Roberto
    Romario, Uberto Fumagalli
    Rimassa, Lorenza
    Bozzarelli, Silvia
    Donini, Annibale
    Graziosi, Luigina
    De Angelis, Verena
    De Manzoni, Giovanni
    Bencivenga, Maria
    Mengardo, Valentina
    Parma, Emilio
    Milandri, Carlo
    Mura, Gianni
    Signorini, Alessandra
    Baiocchi, Gianluca
    Molfino, Sarah
    Sgroi, Giovanni
    Steccanella, Francesca
    Rausei, Stefano
    Proserpio, Ilaria
    Vigano, Jacopo
    Brugnatelli, Silvia
    Rinnovati, Andrea
    Santi, Stefano
    Ercolani, Giorgio
    Foca, Flavia
    Valmorri, Linda
    Amadori, Dino
    Frassineti, Giovanni Luca
    CANCERS, 2020, 12 (10) : 1 - 13
  • [35] Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
    O Nehls
    H Oettle
    J T Hartmann
    R-D Hofheinz
    H G Hass
    M S Horger
    U Koppenhöfer
    A Hochhaus
    J Stieler
    J Trojan
    M Gregor
    B Klump
    British Journal of Cancer, 2008, 98 : 309 - 315
  • [36] Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
    Zhaoqing Tang
    Yan Wang
    Yiyi Yu
    Yuehong Cui
    Liang Liang
    Chen Xu
    Zhenbin Shen
    Kuntang Shen
    Xuefei Wang
    Tianshu Liu
    Yihong Sun
    BMC Medicine, 20
  • [37] Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
    Tang, Zhaoqing
    Wang, Yan
    Yu, Yiyi
    Cui, Yuehong
    Liang, Liang
    Xu, Chen
    Shen, Zhenbin
    Shen, Kuntang
    Wang, Xuefei
    Liu, Tianshu
    Sun, Yihong
    BMC MEDICINE, 2022, 20 (01)
  • [38] Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Chin, Keisho
    Cho, Haruhiko
    Katai, Hitoshi
    Terashima, Masanori
    Ito, Seiji
    Hirao, Motohiro
    Yoshida, Kazuhiro
    Oki, Eiji
    Sasako, Mitsuru
    Emi, Yasunori
    Bando, Hideaki
    Kawashima, Yoshiyuki
    Fukunaga, Tetsu
    Gotoh, Masahiro
    Ishibashi, Takako
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [39] Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
    Scheithauer, W
    Kornek, GV
    Raderer, M
    Schüll, B
    Schmid, K
    Kovats, E
    Schneeweiss, B
    Lang, F
    Lenauer, A
    Depisch, D
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) : 1307 - 1312
  • [40] Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric adenocarcinoma (FRUTINEOGA): A multicenter, phase II study
    Wu, Liucheng
    Qin, Yuzhou
    Huang, Mingwei
    Long, Di
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345